P
14.58
-0.12 (-0.82%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Phathom Pharmaceuticals, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.25 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.28% |
| 机构持股比例 | 84.77% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 26.00 (HC Wainwright & Co., 78.33%) | 购买 |
| 中 | 21.00 (44.03%) | |
| 低 | 16.00 (Barclays, 9.74%) | 保留 |
| 平均值 | 21.00 (44.03%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 13.88 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 09 Dec 2025 | 16.00 (9.74%) | 保留 | 14.21 |
| HC Wainwright & Co. | 31 Oct 2025 | 26.00 (78.33%) | 购买 | 13.55 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合